Comprehensive Stock Comparison
Compare The Pennant Group, Inc. (PNTG) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | PNTG | 36.3% revenue growth vs FMS's 1.5% |
| Value | FMS | Lower P/E (9.9x vs 25.8x), PEG 1.94 vs 2.57 |
| Quality / Margins | FMS | 5.0% net margin vs PNTG's 3.1% |
| Stability / Safety | FMS | Beta 0.40 vs PNTG's 0.54, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PNTG | +48.0% vs FMS's +0.2% |
| Efficiency (ROA) | FMS | 3.2% ROA vs PNTG's 3.1%, ROIC 5.6% vs 5.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Valuation efficiency (growth/$)
Defensive / Recession hedge
Business Model
What each company does and how it makes money
The Pennant Group operates a network of home health, hospice, and senior living facilities across the United States. It generates revenue primarily from Medicare and Medicaid reimbursements for home health and hospice services—roughly 70% of total revenue—with the remainder coming from private pay and insurance for senior living communities. The company's decentralized operating model—which grants local leaders significant autonomy—creates a competitive advantage through better community integration and operational efficiency compared to more centralized healthcare providers.
Fresenius Medical Care is a global leader in dialysis care and products for patients with chronic kidney failure. It generates revenue through two main segments: dialysis services (about 75% of revenue) from its network of outpatient clinics and hospital contracts, and dialysis products (about 25%) including machines, dialyzers, and related supplies. The company's key advantage is its vertically integrated model—combining clinics, products, and services—which creates patient stickiness and economies of scale in the capital-intensive dialysis industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FMS leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). PNTG leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
FMS is the larger business by revenue, generating $19.6B annually — 20.7x PNTG's $948M. Profitability is closely matched — net margins range from 5.0% (FMS) to 3.1% (PNTG). On growth, PNTG holds the edge at +53.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| RevenueTrailing 12 months | $948M | $19.6B |
| EBITDAEarnings before interest/tax | $60M | $3.3B |
| Net IncomeAfter-tax profit | $30M | $978M |
| Free Cash FlowCash after capex | $33M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +11.2% | +25.6% |
| Operating MarginEBIT ÷ Revenue | +5.5% | +9.3% |
| Net MarginNet income ÷ Revenue | +3.1% | +5.0% |
| FCF MarginFCF ÷ Revenue | +3.5% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +53.2% | -0.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | +8.5% |
Valuation Metrics
At 11.8x trailing earnings, FMS trades at a 70% valuation discount to PNTG's 40.1x P/E. Adjusting for growth (PEG ratio), FMS offers better value at 2.32x vs PNTG's 3.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| Market CapShares × price | $1.2B | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | 40.13x | 11.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.82x | 9.89x |
| PEG RatioP/E ÷ EPS growth rate | 3.99x | 2.32x |
| EV / EBITDAEnterprise value multiple | 26.68x | 6.33x |
| Price / SalesMarket cap ÷ Revenue | 1.24x | 0.59x |
| Price / BookPrice ÷ Book value/share | 3.18x | 0.81x |
| Price / FCFMarket cap ÷ FCF | 24.35x | — |
Profitability & Efficiency
PNTG delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $7 for FMS. FMS carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to PNTG's 1.21x. On the Piotroski fundamental quality scale (0–9), FMS scores 5/9 vs PNTG's 3/9, reflecting solid financial health.
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| ROE (TTM)Return on equity | +7.9% | +6.8% |
| ROA (TTM)Return on assets | +3.1% | +3.2% |
| ROICReturn on invested capital | +5.7% | +5.6% |
| ROCEReturn on capital employed | +7.4% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 1.21x | 0.76x |
| Net DebtTotal debt minus cash | $436M | $9.2B |
| Cash & Equiv.Liquid assets | $17M | $1.6B |
| Total DebtShort + long-term debt | $453M | $10.8B |
| Interest CoverageEBIT ÷ Interest expense | 202.23x | 6.84x |
Total Returns (with DRIP)
A $10,000 investment in FMS five years ago would be worth $7,718 today (with dividends reinvested), compared to $6,436 for PNTG. Over the past 12 months, PNTG leads with a +48.0% total return vs FMS's +0.2%. The 3-year compound annual growth rate (CAGR) favors PNTG at 30.9% vs FMS's 9.1% — a key indicator of consistent wealth creation.
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| YTD ReturnYear-to-date | +21.1% | -0.2% |
| 1-Year ReturnPast 12 months | +48.0% | +0.2% |
| 3-Year ReturnCumulative with dividends | +124.4% | +29.7% |
| 5-Year ReturnCumulative with dividends | -35.6% | -22.8% |
| 10-Year ReturnCumulative with dividends | +123.4% | -28.5% |
| CAGR (3Y)Annualised 3-year return | +30.9% | +9.1% |
Risk & Volatility
FMS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than PNTG's 0.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PNTG currently trades 96.3% from its 52-week high vs FMS's 77.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.40x |
| 52-Week HighHighest price in past year | $35.00 | $30.46 |
| 52-Week LowLowest price in past year | $21.18 | $20.95 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 226K | 518K |
Analyst Outlook
Wall Street rates PNTG as "Buy" and FMS as "Hold". Consensus price targets imply 19.4% upside for FMS (target: $28) vs 15.7% for PNTG (target: $39).
| Metric | PNTGThe Pennant Group… | FMSFresenius Medical… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $39.00 | $28.00 |
| # AnalystsCovering analysts | 7 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 3 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 100 | 104.89 | +4.9% |
| Fresenius Medical C… (FMS) | 100 | 56.36 | -43.6% |
Fresenius Medical C… (FMS) returned -23% over 5 years vs The Pennant Group, … (PNTG)'s -36%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | $251M | $948M | +277.6% |
| Fresenius Medical C… (FMS) | $17.0B | $19.6B | +15.3% |
Fresenius Medical Care AG & Co. KGaA's revenue grew from $17.0B (2016) to $19.6B (2025) — a 1.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 3.9% | 3.1% | -20.6% |
| Fresenius Medical C… (FMS) | 6.9% | 5.0% | -28.2% |
Fresenius Medical Care AG & Co. KGaA's net margin went from 7% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 384.5 | 33.5 | -91.3% |
| Fresenius Medical C… (FMS) | 25.3 | 14.2 | -43.9% |
The Pennant Group, Inc. has traded in a 32x–385x P/E range over 7 years; current trailing P/E is ~40x. Fresenius Medical Care AG & Co. KGaA has traded in a 10x–39x P/E range over 9 years; current trailing P/E is ~12x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| The Pennant Group, … (PNTG) | 0.35 | 0.84 | +140.0% |
| Fresenius Medical C… (FMS) | 1.87 | 1.68 | -10.2% |
Fresenius Medical Care AG & Co. KGaA's EPS grew from $1.87 (2016) to $1.68 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
The Pennant Group, Inc. generated $48M FCF in 2025 (+297% vs 2021). Fresenius Medical Care AG & Co. KGaA generated $0M FCF in 2025 (-100% vs 2021).
PNTG vs FMS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PNTG or FMS a better buy right now?
Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate The Pennant Group, Inc. (PNTG) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PNTG or FMS?
On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus The Pennant Group, Inc. at 40.1x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 9.9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Fresenius Medical Care AG & Co. KGaA wins at 1.94x versus The Pennant Group, Inc.'s 2.57x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — PNTG or FMS?
Over the past 5 years, Fresenius Medical Care AG & Co. KGaA (FMS) delivered a total return of -22.8%, compared to -35.6% for The Pennant Group, Inc. (PNTG). A $10,000 investment in FMS five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PNTG returned +123.4% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PNTG or FMS?
By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus The Pennant Group, Inc.'s 0.54β — meaning PNTG is approximately 36% more volatile than FMS relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 121% for The Pennant Group, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — PNTG or FMS?
Fresenius Medical Care AG & Co. KGaA (FMS) is the more profitable company, earning 5.0% net margin versus 3.1% for The Pennant Group, Inc. — meaning it keeps 5.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FMS leads at 9.3% versus 5.5% for PNTG. At the gross margin level — before operating expenses — FMS leads at 25.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PNTG or FMS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Fresenius Medical Care AG & Co. KGaA (FMS) is the more undervalued stock at a PEG of 1.94x versus The Pennant Group, Inc.'s 2.57x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 9.9x forward P/E versus 25.8x for The Pennant Group, Inc. — 15.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMS: 19.4% to $28.00.
07Which pays a better dividend — PNTG or FMS?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PNTG or FMS better for a retirement portfolio?
For long-horizon retirement investors, Fresenius Medical Care AG & Co. KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (FMS: -28.5%, PNTG: +123.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PNTG and FMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: PNTG is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.